Detalhe da pesquisa
1.
An in vitro pharmacodynamic spiking study of befovacimab, a tissue factor pathway inhibitor monoclonal antibody, in blood samples from patients with severe FVIII deficiency.
Haemophilia
; 27(4): 690-698, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-33915599
2.
Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex vivo dosed haemophilic blood and plasmas.
Haemophilia
; 25(5): 797-806, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-31336410
3.
Evaluating the thrombin generation profiles of four different rFVIII products in FVIII-deficient plasma using FIXa and FXIa activation.
Haemophilia
; 24(5): 815-822, 2018 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-30112856
4.
Use of global assays to monitor emicizumab prophylactic therapy in patients with haemophilia A with inhibitors.
Haemophilia
; 25(2): e121-e123, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30748061
5.
Overcoming delayed in-vitro response to rFVIIa: effects of rFVIIa and rFVIIa analogue (vatreptacog alfa) concentration escalation in whole blood assays.
Blood Coagul Fibrinolysis
; 22(6): 541-6, 2011 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-21681082
6.
Factor VIIa analog has marked effects on platelet function and clot kinetics in blood from patients with hemophilia A.
Blood Coagul Fibrinolysis
; 21(6): 539-46, 2010 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-20581663